Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Moodys
Johnson and Johnson
McKesson
Express Scripts

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

LUCEMYRA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Lucemyra patents expire, and when can generic versions of Lucemyra launch?

Lucemyra is a drug marketed by Us Worldmeds Llc and is included in one NDA.

The generic ingredient in LUCEMYRA is lofexidine hydrochloride. One supplier is listed for this compound. Additional details are available on the lofexidine hydrochloride profile page.

Drug patent expirations by year for LUCEMYRA
Drug Prices for LUCEMYRA

See drug prices for LUCEMYRA

Generic Entry Opportunity Date for LUCEMYRA
Generic Entry Date for LUCEMYRA*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LUCEMYRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
US WorldMeds LLCPhase 2
Frances R LevinPhase 2
Medical University of South CarolinaPhase 2

See all LUCEMYRA clinical trials

Synonyms for LUCEMYRA
(-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene
(+)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene
(S)-Lofexidine
1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-
1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro- (9CI)
1H-Imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-
1H-Imidazole,2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-
2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole
2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline
2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline
2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline
2-[1-(2,6-dichlorophenoxy)ethyl]-2-imidazoline
2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole
2-[1-[2,6-bis(chloranyl)phenoxy]ethyl]-4,5-dihydro-1H-imidazole
2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole
2-Imidazoline 2-(1-(2,6-dichlorophenoxy)ethyl)-
31036-80-3
98L088
A820699
AB00698543_08
AB00698543_09
AB00698543-05
AB00698543-07
AC1L1K1D
AC1Q3Q8L
AKOS015900265
BDBM50019646
Britlofex
C-16142
CAS-31036-80-3
CC-30019
CCG-220521
CHEBI:51368
CHEMBL17860
CS-0013650
D08141
DB04948
DSSTox_CID_3221
DSSTox_GSID_23221
DSSTox_RID_97547
DTXSID7023221
FT-0627970
GTPL9868
HMS2090C03
HMS3713J03
HY-B1052A
IMI019
J-507626
KS-0000103S
KSMAGQUYOIHWFS-UHFFFAOYSA-N
Lofexidina
Lofexidina [INN-Spanish]
Lofexidine
Lofexidine (INN)
Lofexidine [INN:BAN]
Lofexidinum
Lofexidinum [INN-Latin]
LS-79612
NCGC00271513-02
RP29235
SCHEMBL48960
SR-01000763628
SR-01000763628-3
SR-01000763628-4
Tox21_113963
UI82K0T627
UNII-UI82K0T627

US Patents and Regulatory Information for LUCEMYRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Worldmeds Llc LUCEMYRA lofexidine hydrochloride TABLET;ORAL 209229-001 May 16, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Dow
McKinsey
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.